MCID: HYP263
MIFTS: 40

Hypersomnia malady

Categories: Neuronal diseases, Mental diseases

Aliases & Classifications for Hypersomnia

Aliases & Descriptions for Hypersomnia:

Name: Hypersomnia 51 69

Classifications:



Summaries for Hypersomnia

NINDS : 51 Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. Different from feeling tired due to lack of or interrupted sleep at night, persons with hypersomnia are compelled to nap repeatedly during the day, often at inappropriate times such as at work, during a meal, or in conversation. These daytime naps usually provide no relief from symptoms. Patients often have difficulty waking from a long sleep, and may feel disoriented. Other symptoms may include anxiety, increased irritation, decreased energy, restlessness, slow thinking, slow speech, loss of appetite, hallucinations, and memory difficulty. Some patients lose the ability to function in family, social, occupational, or other settings. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Certain medications, or medicine withdrawal, may also cause hypersomnia. Medical conditions including multiple sclerosis, depression, encephalitis, epilepsy, or obesity may contribute to the disorder. Some people appear to have a genetic predisposition to hypersomnia; in others, there is no known cause. Typically, hypersomnia is first recognized in adolescence or young adulthood.

MalaCards based summary : Hypersomnia is related to idiopathic hypersomnia and recurrent hypersomnia, and has symptoms including sleep disturbances, excessive daytime somnolence and sleeplessness. An important gene associated with Hypersomnia is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1), and among its related pathways/superpathways are Hematopoietic cell lineage and Rheumatoid arthritis. The drugs Modafinil and Armodafinil have been mentioned in the context of this disorder. Affiliated tissues include testes, hypothalamus and brain.

Wikipedia : 71 Hypersomnia, or hypersomnolence, is a neurological disorder of excessive time spent sleeping or... more...

Related Diseases for Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
id Related Disease Score Top Affiliating Genes
1 idiopathic hypersomnia 12.4
2 recurrent hypersomnia 12.1
3 idiopathic hypersomnia without long sleep time 12.0
4 idiopathic hypersomnia with long sleep time 11.9
5 kleine-levin hibernation syndrome 11.0
6 myotonic dystrophy 2 10.8
7 dystonia, dopa-responsive, due to sepiapterin reductase deficiency 10.8
8 narcolepsy 10.5
9 imaizumi kuroki syndrome 10.2 HCRT HLA-DQB1
10 hodgkin's paragranuloma 10.2 HCRT HLA-DQB1
11 apple allergy 10.2 HLA-DQB1 HLA-DRB1
12 hemoglobin d disease 10.2 HLA-DQB1 HLA-DRB1
13 bilateral parasagittal parieto-occipital polymicrogyria 10.2 HLA-DQB1 HLA-DRB1
14 immune deficiency, familial variable 10.2 HLA-DQB1 HLA-DRB1
15 lin-gettig syndrome 10.2 HLA-DQB1 HLA-DRB1
16 midline interhemispheric variant of holoprosencephaly 10.2 HLA-DQB1 HLA-DRB1
17 autosomal dominant intermediate charcot-marie-tooth 10.2 HLA-DQB1 HLA-DRB1
18 renal agenesis meningomyelocele mullerian defect 10.2 HLA-DQB1 HLA-DRB1
19 sleep apnea 10.2
20 distal trisomy 14q 10.2 HLA-DQB1 HLA-DRB1
21 learning disability 10.2 HLA-DQB1 HLA-DRB1
22 linear lichen planus 10.2 HLA-DQB1 HLA-DRB1
23 night blindness 10.2 HLA-DQB1 HLA-DRB1
24 neonatal antiphospholipid syndrome 10.2 HLA-DQB1 HLA-DRB1
25 clostridium difficile colitis 10.2 HLA-DQB1 HLA-DRB1
26 myofibroma 10.2 HLA-DQB1 HLA-DRB1
27 oromandibular dystonia 10.2 HLA-DQB1 HLA-DRB1
28 rud syndrome 10.2 HCRT HCRTR1
29 cryptococcosis 10.2 HLA-DQB1 HLA-DRB1
30 myopathy, distal, with early respiratory failure, autosomal dominant 10.1 HCRT HLA-DQB1
31 bickerstaff brainstem encephalitis 10.1 HLA-DQB1 HLA-DRB1
32 anaerobic meningitis 10.1 HLA-DQB1 HLA-DRB1
33 low anorectal malformation 10.1 HLA-DQB1 HLA-DRB1
34 ragweed sensitivity 10.1 HLA-DQB1 HLA-DRB1
35 folinic acid-responsive seizures 10.1 HLA-DQB1 HLA-DRB1
36 niemann-pick disease 10.1 HCRT HLA-DRB1
37 migraine with aura 10.1 CHKB HLA-DQB1
38 lymphangiectasia, intestinal 10.1 HLA-DQB1 HLA-DRB1
39 breast hemangiopericytoma 10.0 HCRT HCRTR1
40 cervical adenoid basal carcinoma 10.0 HCRT HLA-DQB1 HLA-DRB1
41 parasitic helminthiasis infectious disease 10.0 HLA-DQB1 HLA-DRB1
42 choreatic disease 10.0 HCRT HLA-DQB1 HLA-DRB1
43 b-cell lymphomas 10.0 HLA-DQB1 HLA-DRB1
44 anterior corneal pigmentation 10.0 HLA-DQB1 HLA-DRB1
45 myotonic dystrophy 10.0
46 sleep disorder 9.9
47 prader-willi syndrome 9.9
48 neuronitis 9.9
49 brain injury 9.9
50 traumatic brain injury 9.9

Graphical network of the top 20 diseases related to Hypersomnia:



Diseases related to Hypersomnia

Symptoms & Phenotypes for Hypersomnia

UMLS symptoms related to Hypersomnia:


sleep disturbances, excessive daytime somnolence, sleeplessness, [d]sleep disturbances (& [hypersomnia] or [insomnia]), insomnia with sleep apnea, unspecified, hypersomnia with sleep apnea, unspecified, disruption of 24 hour sleep wake cycle, unspecified

Drugs & Therapeutics for Hypersomnia

Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68693-11-8 4236
2
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112111-43-0
3
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
4
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
5
Citalopram Approved Phase 4 59729-33-8 2771
6 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
7 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Wakefulness-Promoting Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Antidepressive Agents Phase 4,Phase 2
10 Psychotropic Drugs Phase 4,Phase 2
11 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
12
Serotonin Phase 4,Phase 2 50-67-9 5202
13 Muscarinic Antagonists Phase 4
14 Cholinergic Agents Phase 4
15 Cholinergic Antagonists Phase 4
16 Serotonin Agents Phase 4,Phase 2
17 Serotonin Uptake Inhibitors Phase 4
18 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
19 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 1
20 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
21 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
22 Parasympatholytics Phase 4
23 Dopamine Agents Phase 4,Phase 2,Phase 1
24 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 1
25 Antidepressive Agents, Second-Generation Phase 4
26 Autonomic Agents Phase 4,Phase 2,Phase 1
27 Antiparkinson Agents Phase 4,Phase 2
28 Anesthetics Phase 4
29
Morphine Approved, Investigational Phase 3 57-27-2 5288826
30
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
31
Caffeine Approved, Nutraceutical Phase 2, Phase 3 58-08-2 2519
32
Dehydroepiandrosterone Approved, Nutraceutical Phase 2, Phase 3 53-43-0 9860744
33 Analgesics Phase 3
34 Narcotics Phase 3
35 Analgesics, Opioid Phase 3
36 Central Nervous System Depressants Phase 3,Phase 2
37
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
38 Adjuvants, Immunologic Phase 2, Phase 3
39 Histamine H3 Antagonists Phase 3
40 Phosphodiesterase Inhibitors Phase 2, Phase 3
41 Purinergic P1 Receptor Antagonists Phase 2, Phase 3
42 DHEA (Dehydroepiandrosterone) Nutraceutical Phase 2, Phase 3
43
Levodopa Approved Phase 2 59-92-7 6047
44
Lisuride Approved Phase 2 18016-80-3 28864
45
Amphetamine Approved, Illicit Phase 2,Phase 1 300-62-9 5826 3007
46
Riluzole Approved, Investigational Phase 2 1744-22-5 5070
47
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
48
Clarithromycin Approved Phase 2 81103-11-9 84029
49
Flumazenil Approved Phase 1, Phase 2 78755-81-4 3373
50
Betahistine Approved Phase 2 5638-76-6 2366

Interventional clinical trials:

(show top 50) (show all 82)
id Name Status NCT ID Phase
1 Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder Completed NCT01080807 Phase 4
2 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4
3 Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance Completed NCT00711516 Phase 4
4 Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue. Completed NCT00208715 Phase 4
5 Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder Completed NCT01541475 Phase 4
6 Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management Completed NCT00801892 Phase 4
7 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4
8 Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea Terminated NCT00730041 Phase 4
9 Palliative Morphine With or Without Concurrent Modafinil Unknown status NCT01766323 Phase 3
10 Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder Completed NCT00758498 Phase 3
11 Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD Completed NCT00080288 Phase 3
12 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3
13 PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3
14 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107809 Phase 3
15 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3
16 Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome Completed NCT00079677 Phase 3
17 Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS) Completed NCT00078325 Phase 3
18 Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Completed NCT00214968 Phase 3
19 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3
20 Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3
21 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Completed NCT00078312 Phase 3
22 Caffeine for Excessive Daytime Somnolence in Parkinson's Disease Completed NCT00459420 Phase 2, Phase 3
23 Efficacy and Safety of DHEA for Myotonic Dystrophy Completed NCT00167609 Phase 2, Phase 3
24 Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL Completed NCT00236080 Phase 3
25 Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Completed NCT01638403 Phase 3
26 "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Active, not recruiting NCT02348619 Phase 3
27 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Active, not recruiting NCT02348606 Phase 3
28 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Active, not recruiting NCT02348593 Phase 3
29 "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" Enrolling by invitation NCT02348632 Phase 3
30 Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury Terminated NCT00983437 Phase 3
31 Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury Terminated NCT00893789 Phase 3
32 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2
33 Flumazenil for the Treatment of Primary Hypersomnia Completed NCT01183312 Phase 1, Phase 2
34 VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness Completed NCT00467441 Phase 2
35 Pilot Study of Melatonin and Epilepsy Completed NCT00965575 Phase 2
36 Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features Completed NCT00585585 Phase 2
37 A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer Completed NCT01746043 Phase 2
38 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2
39 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2
40 Riluzole to Treat Major Depression Completed NCT00026052 Phase 2
41 Chloral Hydrate to Perform Auditory Brainstem Response (ABR) Completed NCT00949780 Phase 2
42 Lisuride Patch to Treat Parkinson's Disease Completed NCT00089622 Phase 2
43 A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Recruiting NCT02512588 Phase 2
44 Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy Recruiting NCT02806908 Phase 2
45 Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA Recruiting NCT02806895 Phase 2
46 A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness Recruiting NCT03037203 Phase 2
47 Riluzole to Treat Depression in Bipolar Disorder Terminated NCT00054704 Phase 2
48 Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder Terminated NCT00805493 Phase 2
49 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT01624480 Phase 1
50 Effect of Armodafinil on Simulated Driving Recruiting NCT02468856 Phase 1

Search NIH Clinical Center for Hypersomnia

Genetic Tests for Hypersomnia

Anatomical Context for Hypersomnia

MalaCards organs/tissues related to Hypersomnia:

39
Testes, Hypothalamus, Brain, Eye, Pituitary, Amygdala, Thalamus

Publications for Hypersomnia

Articles related to Hypersomnia:

(show top 50) (show all 341)
id Title Authors Year
1
Case Report of a Patient With Idiopathic Hypersomnia and a Family History of Malignant Hyperthermia Undergoing General Anesthesia: An Overview of the Anesthetic Considerations. ( 28328583 )
2017
2
Diurnal and nocturnal cardiovascular variability and heart rate arousal response in idiopathic hypersomnia. ( 27810179 )
2016
3
The effects of Transcranial Direct Current Stimulation (tDCS) on Idiopathic Hypersomnia: a pilot study. ( 27548094 )
2016
4
Urine Toxicology in Adults Evaluated for a Central Hypersomnia and How the Results Modify the Physician's Diagnosis. ( 27568897 )
2016
5
Recovery of Hypersomnia Concurrent With Recovery of an Injured Ascending Reticular Activating System in a Stroke Patient: A Case Report. ( 26765455 )
2016
6
Migraine with brainstem aura presenting as recurrent hypersomnia (Kleine-Levin syndrome). ( 27343267 )
2016
7
French consensus. Idiopathic hypersomnia: Investigations and follow-up. ( 27838089 )
2016
8
Idiopathic Hypersomnia and Hypersomnolence Disorder: A Systematic Review of the Literature. ( 26895727 )
2016
9
Injury of the Ascending Reticular Activating System in Patients With Fatigue and Hypersomnia Following Mild Traumatic Brain Injury: Two Case Reports. ( 26871783 )
2016
10
Menstruation-Related Hypersomnia Treated with Hormonal Contraception: Case Report and Review of Literature. ( 26932284 )
2016
11
Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review. ( 26847972 )
2016
12
Evaluation of polygenic risks for narcolepsy and essential hypersomnia. ( 27305985 )
2016
13
Behavioral Sleep Medicine Services for Hypersomnia Disorders: A Survey Study. ( 26788889 )
2016
14
Post-stroke hypersomnia. ( 26763039 )
2016
15
Distribution of HLA-DQB1 in Czech Patients with Central Hypersomnias. ( 28083611 )
2016
16
Hypersomnia as the first presentation in a patient with insulinoma: A case report and review of the literature. ( 27699047 )
2016
17
[Posterior reversible encephalopathy syndrome of the midbrain and hypothalamus - a case report of uremic encephalopathy presenting with hypersomnia]. ( 26640128 )
2016
18
Disorders of Excessive Daytime Sleepiness Including Narcolepsy and Idiopathic Hypersomnia. ( 27542882 )
2016
19
Recurrent hypersomnia: Report of medication-responsive cases. ( 26483951 )
2015
20
Misdiagnosis of menstruation-related recurrent hypersomnia as epilepsy in a patient with generalized epileptic discharges. ( 25878739 )
2015
21
Central Hypersomnia. ( 26072339 )
2015
22
Bifrontal Anodal Transcranial Direct Current Stimulation (tDCS) Improves Daytime Vigilance and Sleepiness in aA Patient With Organic Hypersomnia Following Reanimation. ( 26077954 )
2015
23
Central Disorders of Hypersomnolence: Focus on the Narcolepsies and Idiopathic Hypersomnia. ( 26149554 )
2015
24
Evaluation of the Effect of Modafinil on Cognitive Functions in Patients with Idiopathic Hypersomnia with P300. ( 26116438 )
2015
25
Characteristics of patients with hypersomnia by actigraphy. ( 25818262 )
2015
26
Hypersomnia subtypes, sleep and relapse in bipolar disorder. ( 25515854 )
2015
27
Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control Study. ( 26564129 )
2015
28
Hypersomnia in Mood Disorders: a Rapidly Changing Landscape. ( 26258003 )
2015
29
Idiopathic hypersomnia. ( 26599679 )
2015
30
Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis. ( 25576137 )
2015
31
CDH13 and HCRTR2 May Be Associated with Hypersomnia Symptom of Bipolar Depression: A Genome-Wide Functional Enrichment Pathway Analysis. ( 26207136 )
2015
32
The Prevalence and Characteristics of Primary Headache and Dream-Enacting Behaviour in Japanese Patients with Narcolepsy or Idiopathic Hypersomnia: A Multi-Centre Cross-Sectional Study. ( 26418536 )
2015
33
Response to the letter to the editor from Dr. Kawada, "Characteristics of patients with hypersomnia by actigraphy". ( 25818261 )
2015
34
IL-1I^ and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder. ( 26241349 )
2015
35
Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage. ( 25680985 )
2015
36
An association analysis of HLA-DQB1 with narcolepsy without cataplexy and idiopathic hypersomnia with/without long sleep time in a Japanese population. ( 27081540 )
2015
37
Recurrent hypersomnia in an 18-year old boy: CSF hypocretin level and MSLT findings. ( 26323648 )
2015
38
Hypersomnia with dilated pupils in adenosine monophosphate deaminase (AMPD) deficiency. ( 24033727 )
2014
39
Cortical-subcortical interactions in hypersomnia disorders: mechanisms underlying cognitive and behavioral aspects of the sleep-wake cycle. ( 25309500 )
2014
40
Diffusion tensor imaging in a patient with cerebral palsy and hypersomnia. ( 24269132 )
2014
41
Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. ( 24953480 )
2014
42
Modafinil in the treatment of idiopathic hypersomnia without long sleep time-a randomized, double-blind, placebo-controlled study. ( 25196321 )
2014
43
Usefulness of genetic characterization of narcolepsy and hypersomnia on phenotype definition: a study in Portuguese patients. ( 24399620 )
2014
44
Infantile epileptic encephalopathy, transient choreoathetotic movements, and hypersomnia due to a De Novo missense mutation in the SCN2A gene. ( 24710820 )
2014
45
Manual characterization of sleep spindle index in patients with narcolepsy and idiopathic hypersomnia. ( 24800086 )
2014
46
Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. ( 24854887 )
2014
47
A case of herpes simplex encephalitis with hypersomnia and low orexin level in the cerebrospinal fluid. ( 24705834 )
2014
48
Sleepiness and Performance Is Disproportionate in Patients with Non-Organic Hypersomnia in Comparison to Patients with Narcolepsy and Mild to Moderate Obstructive Sleep Apnoea. ( 25377356 )
2014
49
Unusual presentation of hypothalamic hamartoma with hypersomnia in an adult patient. ( 25042667 )
2014
50
Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report. ( 24554692 )
2014

Variations for Hypersomnia

Expression for Hypersomnia

Search GEO for disease gene expression data for Hypersomnia.

Pathways for Hypersomnia

Pathways related to Hypersomnia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.31 HLA-DQB1 HLA-DRB1
2 11.21 HLA-DQB1 HLA-DRB1
3 11.01 HLA-DQB1 HLA-DRB1
4 10.7 HLA-DQB1 HLA-DRB1
5
Show member pathways
10.35 CHKB CPT1B

GO Terms for Hypersomnia

Cellular components related to Hypersomnia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 9.43 CARTPT HCRT
2 trans-Golgi network membrane GO:0032588 9.4 HLA-DQB1 HLA-DRB1
3 endocytic vesicle membrane GO:0030666 9.37 HLA-DQB1 HLA-DRB1
4 ER to Golgi transport vesicle membrane GO:0012507 9.32 HLA-DQB1 HLA-DRB1
5 transport vesicle membrane GO:0030658 9.26 HLA-DQB1 HLA-DRB1
6 clathrin-coated endocytic vesicle membrane GO:0030669 9.16 HLA-DQB1 HLA-DRB1
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-DQB1 HLA-DRB1
8 MHC class II protein complex GO:0042613 8.62 HLA-DQB1 HLA-DRB1

Biological processes related to Hypersomnia according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.54 CARTPT HCRT HCRTR1
2 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.49 HLA-DQB1 HLA-DRB1
3 T cell costimulation GO:0031295 9.48 HLA-DQB1 HLA-DRB1
4 interferon-gamma-mediated signaling pathway GO:0060333 9.46 HLA-DQB1 HLA-DRB1
5 antigen processing and presentation GO:0019882 9.43 HLA-DQB1 HLA-DRB1
6 neuropeptide signaling pathway GO:0007218 9.43 CARTPT HCRT HCRTR1
7 feeding behavior GO:0007631 9.4 HCRT HCRTR1
8 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.32 HLA-DQB1 HLA-DRB1
9 positive regulation of transmission of nerve impulse GO:0051971 9.16 CARTPT HCRT
10 humoral immune response mediated by circulating immunoglobulin GO:0002455 8.96 HLA-DQB1 HLA-DRB1
11 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.62 HLA-DQB1 HLA-DRB1

Molecular functions related to Hypersomnia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.16 CARTPT HCRT
2 peptide antigen binding GO:0042605 8.96 HLA-DQB1 HLA-DRB1
3 MHC class II receptor activity GO:0032395 8.62 HLA-DQB1 HLA-DRB1

Sources for Hypersomnia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....